Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
What is your preferred adjuvant treatment option for a patient with stage III BRAF-mutated melanoma and a history of a solid organ transplantation on immunosuppressants?
Related Questions
How would you manage a large area of multiple, recurrent cutaneous squamous cell carcinomas of the scalp with ulcerations and non-healing areas despite cryotherapy, multiple Mohs procedures, and 5-FU?
Do you obtain MRI for cutaneous SCC with microscopic PNI to assess for gross perineural tumor spread?
How would you manage a cardiac metastasis from Merkel cell carcinoma?
In patients with multiple basal cell carcinoma lesions on vismodegib, would you hold vismodegib while delivering radiation therapy to one locally advanced BCC lesion that was not amenable to surgery?
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
How do you approach the management of patients with locally advanced unresectable mucosal melanoma in the head and neck region?
What is the role of adrenalectomy in managing isolated recurrence of stage IIIc melanoma, occurring 2 years after the original diagnosis, in a patient who declined adjuvant therapy?
How would you sequence lifileucel (TIL therapy) in a patient with metastatic melanoma who is BRAF wild-type (BRAF WT) and progressed on adjuvant Nivolumab?
Would you consider adjuvant immunotherapy for a patient with high-risk (N3 nodes) Merkel cell carcinoma following definitive surgical resection and adjuvant radiation therapy?
How would you treat locally advanced melanoma of the scalp with several in transit lesions and a metastatic lesion to the parotid if the patient is progressing on immunotherapy such as pembrolizumab?
